Product Overview
[Drug Name]
Generic Name: Enteric-Coated Aspirin Tablets
Trade Name: Neptune Enteric-Coated Aspirin Tablets 25mg x 100 Tablets
[Main Ingredient]
The main ingredient of this product is aspirin.
[Properties]
Enteric-Coated Aspirin Tablets are enteric-coated tablets that appear white after the coating is removed.
[Indications/Main Functions]
This product is a nonsteroidal anti-inflammatory drug (NSAID). It is clinically indicated for the following conditions. 1. Analgesia and Antipyretic: It can relieve mild to moderate pain, such as headaches, toothaches, neuralgia, muscle pain, and menstrual pain. It is also used to reduce fever in colds and flu. This product only relieves symptoms and does not treat the underlying cause of pain and fever. Therefore, other medications must be used to treat the underlying cause. 2. Anti-inflammatory and Anti-rheumatic: It is commonly used to treat rheumatic fever. It can reduce fever, improve joint symptoms, and lower erythrocyte sedimentation rate, but it does not eliminate the underlying pathology of rheumatic fever. Changes, nor can it treat and prevent heart damage and other complications. 3. Arthritis: In addition to rheumatoid arthritis, this product is also used to treat rheumatoid arthritis, which can improve symptoms, but the cause must be treated at the same time. In addition, this product is also used for skeletal muscle pain in osteoarthritis, ankylosing spondylitis, juvenile arthritis and other non-rheumatic inflammations, and can also relieve symptoms. However, this product has been rarely used in these diseases in recent years. 4. Antithrombotic: This product has an inhibitory effect on platelet aggregation and can prevent thrombosis. It is clinically used to prevent transient ischemic attacks, myocardial infarction, atrial fibrillation, artificial heart valves, arteriovenous fistula or other post-operative thrombosis. It can also be used to treat unstable angina. 5. Pediatric use for mucocutaneous lymph node syndrome (Kawasaki disease) treatment.
[Specification]
25mg*100 Tablets
[Usage and Dosage]
Oral. 1. Common dosage for adults (1) Antipyretic and analgesic, 0.3~0.69 once, 3 times a day, once every 4 hours if necessary, (⑵2) Anti-rheumatic, 3~6g a day, orally in 4 doses, (3) Inhibit platelet aggregation, use a small dose, such as 80mg~300mg per day, once a day. (4) Treatment of biliary ascariasis, 1g once. 2~3 times a day, for 2~3 consecutive days: stop using after 24 hours of paroxysmal colic, and then perform anthelmintic treatment. 2 hours Children are commonly used () antipyretic and analgesic, daily body surface area 1, 59/m2, divided into 4 to 6 times orally, or each time according to body weight 5 to 10mg/kg, or each time 6mg per year, once every 4 to 6 hours if necessary. (2) Anti-rheumatic, daily body weight 80 to 100mg/kg, divided into 3 to 4 times, if 1 to 2 weeks without efficacy, the dosage can be adjusted according to the blood drug concentration, some cases need to be increased to daily, small skin complex after fever, 1 to 4 times, continuous use for 2 months or more, thrombocytosis, blood in a hypercoagulable state during the period, daily 510mg/kg, once.
[Adverse Reactions [Should be omitted]
Generally, antipyretic and analgesic doses rarely cause adverse reactions. However, long-term, high-dose use (such as for rheumatic fever) and especially when blood concentrations exceed 200 μg/mL are more likely to cause adverse reactions. The higher the blood concentration, the more pronounced the adverse reactions. 1. Common gastrointestinal reactions (incidence 3%-9%) include nausea, vomiting, and upper abdominal discomfort or pain (caused by direct irritation of the gastric mucosa), which usually disappear after discontinuation of the drug. Long-term or high-dose use may cause gastrointestinal bleeding or ulcers. 2. Central nervous system effects: Reversible tinnitus and hearing loss may occur, often after a certain course of treatment, when blood concentrations are elevated. Hypersensitivity reactions occur after administration of aspirin at concentrations of 200-300 μg/mL. These reactions occur in 2% of patients and manifest as asthma, angioedema, or mucocutaneous edema. In susceptible individuals, respiratory distress develops rapidly after administration, and in severe cases, death is a condition known as aspirin asthma. Some cases present with a triad of aspirin allergy, asthma, and nasal polyps. This condition is often associated with genetic and environmental factors. Liver and kidney damage is dose-dependent, particularly with excessive doses resulting in blood concentrations exceeding 250 μg/mL. These damages are reversible and resolve after discontinuation of the drug. However, there have been reports of renal papillary necrosis.
[Contraindications]
1. This product is contraindicated in patients with allergies. 2. Enteric-coated aspirin tablets should be contraindicated in the following situations: (1) Active ulcer disease or gastrointestinal bleeding caused by other reasons. (2) Hemophilia or thrombocytopenia. (3) People with a history of allergy to aspirin or other nonsteroidal anti-inflammatory drugs, especially those with asthma, neuroangioedema or shock.
[Drug Interactions]
1. The efficacy is not enhanced when used with other nonsteroidal anti-inflammatory analgesics, because enteric-coated aspirin tablets can reduce the bioavailability of other nonsteroidal anti-inflammatory drugs. In addition, gastrointestinal side effects (including ulcers and bleeding) are increased; in addition, due to the enhanced inhibitory effect on platelet aggregation, the risk of bleeding in other parts of the body can also be increased. Long-term and large-scale use of this product with acetaminophen may cause kidney disease including renal papillary necrosis, renal cancer or bladder cancer. 2. When used with any drug that can cause hypoprothrombinemia, thrombocytopenia, decreased platelet aggregation function or gastrointestinal ulcer bleeding, there is a risk of aggravating coagulation disorders and causing bleeding. 3. When used with anti- The concomitant use of coagulants (dicoumarol, heparin, etc.) and thrombolytics (streptokinase, urokinase) may increase the risk of bleeding. 4. Urine alkalinizing drugs (sodium bicarbonate, etc.) and antacids (long-term and large-scale use) may increase the excretion of this product in urine, causing a decrease in blood drug concentration. However, when the blood drug concentration of this product has reached a stable state and the alkaline drug is discontinued, the blood drug concentration of this product may rise to a toxic level. Carbonic anhydrase inhibitors can alkalinize urine, but can cause metabolic acidosis, which not only reduces the blood drug concentration, but also makes this product Increased penetration into brain tissue increases toxicity. 5. Uric acid-binding drugs can reduce the excretion of this drug, increasing its blood concentration. Adding uricosides to patients whose blood concentration of this drug has reached a stable state may lead to increased blood concentrations and increased toxicity. 6. Glucocorticoids (hormones) can increase the excretion of salicylates. To maintain the blood concentration of this drug when used concomitantly, the dosage of this drug should be increased if necessary. Long-term concomitant use of this drug with hormones, especially in large quantities, may increase Risk of gastrointestinal ulcer and bleeding. Therefore, it is not recommended to use these two drugs at the same time in clinical practice. 7. The hypoglycemic effect of islet or oral hypoglycemic drugs can be enhanced and accelerated by using this product together. 8. When used together with methotrexate (MTX), it can reduce the binding of methotrexate to protein, reduce its excretion from the kidneys, increase the blood concentration and increase the toxic reaction. 9. The uricosuric effect of probenecid or sulfinpyraone can be reduced by using this product together; when the blood concentration of salicylate is >50g/m, it will be significantly reduced, and even more so when it is >100150μg/m. In addition, probenecid can reduce the clearance rate of salicylate from the kidneys, thereby increasing the blood concentration of the latter.
[Precautions]
1. Cross-allergic reaction. When allergic to this product, you may also be allergic to another salicylate drug or another non-salicylic acid non-steroidal anti-inflammatory drug. But it is not absolute. You must be alert to the possibility of cross-allergy. 2. Interference with diagnosis: (1) Long-term use of each When the daily dosage exceeds 2 or 4 g, the copper sulfate urine glucose test may produce a false positive. The glucose enzyme urine glucose test may produce a false negative. (2) It may interfere with the urine ketone body test. (3) When the blood drug concentration exceeds 130 μg/mL, the colorimetric method for measuring blood uric acid may produce a false high value, but the uricase method is not affected. (4) The fluorescence method for measuring urine 5-hydroxy indole acetic acid (5-HIAA) may be interfered with by this product. (5) The determination of urine vanillyl mandelic acid (VMA) may result in different results due to different methods. The results can be high or low. (6) Because this product inhibits platelet aggregation, it can prolong bleeding time. A dose as low as 40 mg/day can also affect platelet function, but clinically, small doses (<150 mg/day) have not been found to cause liver function tests. When the blood concentration is >250 μg/m, alanine aminotransferase, aspartate aminotransferase and serum alkaline phosphatase may have abnormal changes, which can return to normal when the dose is reduced. (7) High-dose use, especially blood concentrations >300 μg /ml, the prothrombin time can be prolonged. (8) When the daily dosage exceeds 5g, the serum cholesterol is low. (9) Because this product acts on the renal tubules, it increases potassium excretion, which can lead to a decrease in blood potassium. When this product is used in large doses, lower results can be obtained by measuring serum thyroxine (T4) and triiodothyronine (T3) by radioimmunoassay. Because this product competes with phenolsulfonphthalein for excretion in the renal tubules, the excretion of phenolsulfonphthalein is reduced (i.e., PSP excretion test). 3. It should be used with caution in the following situations: (1) When there is asthma and other allergic reactions. (2) People with glucose-6-phosphate dehydrogenase deficiency (this product) (3) Gout (This product may affect the effects of other uricosuric drugs and may cause uric acid retention at low doses.) (4) When liver function is impaired, it may aggravate liver toxicity and bleeding tendency. Patients with liver insufficiency and cirrhosis are prone to adverse kidney reactions. (5) Heart failure or hypertension. Large doses of the drug may cause heart failure or pulmonary edema. (6) Renal insufficiency may increase the risk of kidney toxicity. (7) Patients with thrombocytopenia. 4. Long-term high-dose use. Regular checks of hematocrit, liver function, and serum salicylic acid levels should be performed.
[Use in Elderly Patients]
Elderly patients are more susceptible to toxic reactions when taking this drug due to decreased renal function.
[Pharmacology and Toxicology]
Aspirin inhibits platelet thromboxane A2 production, thereby inhibiting platelet aggregation. This mechanism is due to irreversible inhibition of cyclooxygenase synthesis; this inhibitory effect is particularly pronounced because these enzymes cannot be resynthesized within platelets. Aspirin also has other inhibitory effects on platelets. Therefore, it is widely used in cardiovascular disease. Aspirin is an acidic non-steroidal drug with antipyretic, analgesic, and anti-inflammatory properties. It is commonly taken orally for pain relief and treatment. Aspirin can reduce body temperature and relieve joint and muscle pain, such as colds and flu. Aspirin is also used for chronic and acute inflammatory conditions, such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. High doses of 4-8g per day are generally effective for these conditions. Preclinical safety data in animal studies have shown that high doses of salicylic acid cause renal damage but no other organ damage. In vivo and in vitro studies have shown that aspirin is neither teratogenic nor carcinogenic. Salicylates may be teratogenic in different animal species. There are also reports that use during pregnancy can interfere with ovarian implantation, cause embryotoxicity and fetotoxicity, and lead to learning disabilities in offspring.
